The translocator protein as a drug target in Alzheimer's disease

Sook W. Chua, Michael Kassiou, Lars M. Ittner*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

19 Citations (Scopus)


The translocator protein (TSPO) recently emerged as a potential drug target in Alzheimer's disease (AD). This has been fuelled mainly by positron emission topography studies that show the upregulation of TSPO in AD, especially in relation to microgliosis and astrogliosis in amyloid-β and tau pathology. Although data as to the exact role of TSPO in AD is still inconclusive, TSPO appears to be involved in neuroinflammatory processes and AD has been shown to involve substantial inflammation. Therefore, further development and investigation of the pharmacological effect of TSPO ligands in AD pathology are warranted.

Original languageEnglish
Pages (from-to)439-448
Number of pages10
JournalExpert Review of Neurotherapeutics
Issue number4
Publication statusPublished - Apr 2014
Externally publishedYes


  • Alzheimer's disease
  • Drug development
  • Microglia
  • Neuroinflammation
  • Positron emission topography
  • Translocator protein
  • TSPO


Dive into the research topics of 'The translocator protein as a drug target in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this